Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDK4 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MDM2 amplification + CDK4 amplification (1)

MDM2 amplification + CDK4 amplification (1)

›

CDK4 amplification	Non Small Cell Lung Cancer	CDK4 amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
CDK4 amplification	Soft Tissue Sarcoma	CDK4 amplification	Soft Tissue Sarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDK4 amplification	Melanoma	CDK4 amplification	Melanoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
CDK4 amplification	Osteosarcoma	CDK4 amplification	Osteosarcoma	palbociclib + lenvatinib Sensitive: C3 – Early Trials palbociclib + lenvatinib Sensitive : C3	palbociclib + lenvatinib Sensitive: C3 – Early Trials palbociclib + lenvatinib Sensitive : C3
CDK4 amplification	Diffuse Large B Cell Lymphoma	CDK4 amplification	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
CDK4 amplification	Glioblastoma	CDK4 amplification	Glioblastoma	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
CDK4 amplification	Liposarcoma	CDK4 amplification	Liposarcoma	docetaxel + eribulin mesylate Sensitive: D – Preclinical docetaxel + eribulin mesylate Sensitive : D	docetaxel + eribulin mesylate Sensitive: D – Preclinical docetaxel + eribulin mesylate Sensitive : D